nodes	percent_of_prediction	percent_of_DWPC	metapath
Diflunisal—Haemolytic anaemia—Mechlorethamine—lymphatic system cancer	0.0172	0.0172	CcSEcCtD
Diflunisal—Proteinuria—Fludarabine—lymphatic system cancer	0.0158	0.0158	CcSEcCtD
Diflunisal—Protein urine present—Fludarabine—lymphatic system cancer	0.0156	0.0156	CcSEcCtD
Diflunisal—Hearing impaired—Fludarabine—lymphatic system cancer	0.0146	0.0146	CcSEcCtD
Diflunisal—Allergic cutaneous angiitis—Methotrexate—lymphatic system cancer	0.0129	0.0129	CcSEcCtD
Diflunisal—Haemolytic anaemia—Teniposide—lymphatic system cancer	0.0127	0.0127	CcSEcCtD
Diflunisal—Jaundice—Mechlorethamine—lymphatic system cancer	0.0117	0.0117	CcSEcCtD
Diflunisal—Deafness—Fludarabine—lymphatic system cancer	0.0113	0.0113	CcSEcCtD
Diflunisal—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.0112	0.0112	CcSEcCtD
Diflunisal—Visual disturbance—Fludarabine—lymphatic system cancer	0.0106	0.0106	CcSEcCtD
Diflunisal—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.0102	0.0102	CcSEcCtD
Diflunisal—Gastrointestinal haemorrhage—Fludarabine—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Diflunisal—Tinnitus—Mechlorethamine—lymphatic system cancer	0.01	0.01	CcSEcCtD
Diflunisal—Bronchospasm—Teniposide—lymphatic system cancer	0.00975	0.00975	CcSEcCtD
Diflunisal—Proteinuria—Mitoxantrone—lymphatic system cancer	0.0094	0.0094	CcSEcCtD
Diflunisal—Protein urine present—Mitoxantrone—lymphatic system cancer	0.00927	0.00927	CcSEcCtD
Diflunisal—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.00907	0.00907	CcSEcCtD
Diflunisal—Stomatitis—Teniposide—lymphatic system cancer	0.00861	0.00861	CcSEcCtD
Diflunisal—Sweating—Teniposide—lymphatic system cancer	0.00847	0.00847	CcSEcCtD
Diflunisal—Vertigo—Mechlorethamine—lymphatic system cancer	0.00841	0.00841	CcSEcCtD
Diflunisal—Leukocytoclastic vasculitis—Methotrexate—lymphatic system cancer	0.00839	0.00839	CcSEcCtD
Diflunisal—Disorientation—Bleomycin—lymphatic system cancer	0.00826	0.00826	CcSEcCtD
Diflunisal—Dysuria—Fludarabine—lymphatic system cancer	0.00814	0.00814	CcSEcCtD
Diflunisal—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.0077	0.0077	CcSEcCtD
Diflunisal—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00764	0.00764	CcSEcCtD
Diflunisal—Renal failure—Fludarabine—lymphatic system cancer	0.00763	0.00763	CcSEcCtD
Diflunisal—Stomatitis—Fludarabine—lymphatic system cancer	0.00757	0.00757	CcSEcCtD
Diflunisal—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00748	0.00748	CcSEcCtD
Diflunisal—Haematuria—Fludarabine—lymphatic system cancer	0.0074	0.0074	CcSEcCtD
Diflunisal—Flushing—Teniposide—lymphatic system cancer	0.00736	0.00736	CcSEcCtD
Diflunisal—Anorexia—Mechlorethamine—lymphatic system cancer	0.00729	0.00729	CcSEcCtD
Diflunisal—Deafness—Vincristine—lymphatic system cancer	0.00688	0.00688	CcSEcCtD
Diflunisal—Visual impairment—Fludarabine—lymphatic system cancer	0.00672	0.00672	CcSEcCtD
Diflunisal—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00664	0.00664	CcSEcCtD
Diflunisal—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00659	0.00659	CcSEcCtD
Diflunisal—Gastrointestinal haemorrhage—Carmustine—lymphatic system cancer	0.00645	0.00645	CcSEcCtD
Diflunisal—Bronchospasm—Bleomycin—lymphatic system cancer	0.00628	0.00628	CcSEcCtD
Diflunisal—Gastrointestinal haemorrhage—Mitoxantrone—lymphatic system cancer	0.006	0.006	CcSEcCtD
Diflunisal—Chest pain—Teniposide—lymphatic system cancer	0.00588	0.00588	CcSEcCtD
Diflunisal—Confusional state—Teniposide—lymphatic system cancer	0.00568	0.00568	CcSEcCtD
Diflunisal—Oedema—Teniposide—lymphatic system cancer	0.00563	0.00563	CcSEcCtD
Diflunisal—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00563	0.00563	CcSEcCtD
Diflunisal—Stomatitis—Bleomycin—lymphatic system cancer	0.00555	0.00555	CcSEcCtD
Diflunisal—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00552	0.00552	CcSEcCtD
Diflunisal—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00545	0.00545	CcSEcCtD
Diflunisal—Haematuria—Bleomycin—lymphatic system cancer	0.00543	0.00543	CcSEcCtD
Diflunisal—Pruritus—Mechlorethamine—lymphatic system cancer	0.00541	0.00541	CcSEcCtD
Diflunisal—Anorexia—Teniposide—lymphatic system cancer	0.00537	0.00537	CcSEcCtD
Diflunisal—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00523	0.00523	CcSEcCtD
Diflunisal—Dyspnoea—Teniposide—lymphatic system cancer	0.00502	0.00502	CcSEcCtD
Diflunisal—Confusional state—Fludarabine—lymphatic system cancer	0.00499	0.00499	CcSEcCtD
Diflunisal—Dysuria—Vincristine—lymphatic system cancer	0.00498	0.00498	CcSEcCtD
Diflunisal—Oedema—Fludarabine—lymphatic system cancer	0.00495	0.00495	CcSEcCtD
Diflunisal—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00495	0.00495	CcSEcCtD
Diflunisal—Decreased appetite—Teniposide—lymphatic system cancer	0.0049	0.0049	CcSEcCtD
Diflunisal—Renal failure—Carmustine—lymphatic system cancer	0.00489	0.00489	CcSEcCtD
Diflunisal—Vomiting—Mechlorethamine—lymphatic system cancer	0.00486	0.00486	CcSEcCtD
Diflunisal—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00486	0.00486	CcSEcCtD
Diflunisal—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00485	0.00485	CcSEcCtD
Diflunisal—Stomatitis—Carmustine—lymphatic system cancer	0.00484	0.00484	CcSEcCtD
Diflunisal—Rash—Mechlorethamine—lymphatic system cancer	0.00482	0.00482	CcSEcCtD
Diflunisal—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00481	0.00481	CcSEcCtD
Diflunisal—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00479	0.00479	CcSEcCtD
Diflunisal—Flushing—Bleomycin—lymphatic system cancer	0.00474	0.00474	CcSEcCtD
Diflunisal—Anorexia—Fludarabine—lymphatic system cancer	0.00472	0.00472	CcSEcCtD
Diflunisal—Proteinuria—Methotrexate—lymphatic system cancer	0.00468	0.00468	CcSEcCtD
Diflunisal—Feeling abnormal—Teniposide—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Diflunisal—Stomatitis—Vincristine—lymphatic system cancer	0.00462	0.00462	CcSEcCtD
Diflunisal—Protein urine present—Methotrexate—lymphatic system cancer	0.00462	0.00462	CcSEcCtD
Diflunisal—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00461	0.00461	CcSEcCtD
Diflunisal—Sweating—Vincristine—lymphatic system cancer	0.00455	0.00455	CcSEcCtD
Diflunisal—Renal failure—Mitoxantrone—lymphatic system cancer	0.00454	0.00454	CcSEcCtD
Diflunisal—Nausea—Mechlorethamine—lymphatic system cancer	0.00454	0.00454	CcSEcCtD
Diflunisal—Stomatitis—Mitoxantrone—lymphatic system cancer	0.0045	0.0045	CcSEcCtD
Diflunisal—Jaundice—Mitoxantrone—lymphatic system cancer	0.0045	0.0045	CcSEcCtD
Diflunisal—Urticaria—Teniposide—lymphatic system cancer	0.00448	0.00448	CcSEcCtD
Diflunisal—Body temperature increased—Teniposide—lymphatic system cancer	0.00445	0.00445	CcSEcCtD
Diflunisal—Paraesthesia—Fludarabine—lymphatic system cancer	0.00445	0.00445	CcSEcCtD
Diflunisal—Hallucination—Carmustine—lymphatic system cancer	0.00444	0.00444	CcSEcCtD
Diflunisal—Sweating—Mitoxantrone—lymphatic system cancer	0.00443	0.00443	CcSEcCtD
Diflunisal—Dyspnoea—Fludarabine—lymphatic system cancer	0.00442	0.00442	CcSEcCtD
Diflunisal—Haematuria—Mitoxantrone—lymphatic system cancer	0.00441	0.00441	CcSEcCtD
Diflunisal—Dyspepsia—Fludarabine—lymphatic system cancer	0.00436	0.00436	CcSEcCtD
Diflunisal—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00431	0.00431	CcSEcCtD
Diflunisal—Decreased appetite—Fludarabine—lymphatic system cancer	0.00431	0.00431	CcSEcCtD
Diflunisal—Visual impairment—Carmustine—lymphatic system cancer	0.0043	0.0043	CcSEcCtD
Diflunisal—Fatigue—Fludarabine—lymphatic system cancer	0.00427	0.00427	CcSEcCtD
Diflunisal—Hallucination—Vincristine—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Diflunisal—Constipation—Fludarabine—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Diflunisal—Hypersensitivity—Teniposide—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Diflunisal—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Diflunisal—Flushing—Carmustine—lymphatic system cancer	0.00414	0.00414	CcSEcCtD
Diflunisal—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00408	0.00408	CcSEcCtD
Diflunisal—Asthenia—Teniposide—lymphatic system cancer	0.00404	0.00404	CcSEcCtD
Diflunisal—Pruritus—Teniposide—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Diflunisal—Body temperature increased—Fludarabine—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Diflunisal—Diarrhoea—Teniposide—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Diflunisal—Chest pain—Bleomycin—lymphatic system cancer	0.00379	0.00379	CcSEcCtD
Diflunisal—Confusional state—Bleomycin—lymphatic system cancer	0.00366	0.00366	CcSEcCtD
Diflunisal—Vision blurred—Carmustine—lymphatic system cancer	0.00366	0.00366	CcSEcCtD
Diflunisal—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00365	0.00365	CcSEcCtD
Diflunisal—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00363	0.00363	CcSEcCtD
Diflunisal—Oedema—Bleomycin—lymphatic system cancer	0.00363	0.00363	CcSEcCtD
Diflunisal—Vomiting—Teniposide—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Diflunisal—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Diflunisal—Asthenia—Fludarabine—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Diflunisal—Rash—Teniposide—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Diflunisal—Dermatitis—Teniposide—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Diflunisal—Headache—Teniposide—lymphatic system cancer	0.00353	0.00353	CcSEcCtD
Diflunisal—Pruritus—Fludarabine—lymphatic system cancer	0.0035	0.0035	CcSEcCtD
Diflunisal—Anorexia—Bleomycin—lymphatic system cancer	0.00346	0.00346	CcSEcCtD
Diflunisal—Vision blurred—Mitoxantrone—lymphatic system cancer	0.0034	0.0034	CcSEcCtD
Diflunisal—Photosensitivity—Methotrexate—lymphatic system cancer	0.0034	0.0034	CcSEcCtD
Diflunisal—Diarrhoea—Fludarabine—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Diflunisal—Nausea—Teniposide—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Diflunisal—Vertigo—Vincristine—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Diflunisal—Chest pain—Carmustine—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Diflunisal—Paraesthesia—Bleomycin—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Diflunisal—Dyspnoea—Bleomycin—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Diflunisal—Confusional state—Carmustine—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Diflunisal—Oedema—Carmustine—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Diflunisal—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Diflunisal—Decreased appetite—Bleomycin—lymphatic system cancer	0.00316	0.00316	CcSEcCtD
Diflunisal—Visual disturbance—Methotrexate—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Diflunisal—Vomiting—Fludarabine—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Diflunisal—Rash—Fludarabine—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Diflunisal—Dermatitis—Fludarabine—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Diflunisal—Thrombocytopenia—Carmustine—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Diflunisal—Headache—Fludarabine—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Diflunisal—Chest pain—Mitoxantrone—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Diflunisal—Oedema—Vincristine—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Diflunisal—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Diflunisal—Anorexia—Carmustine—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Diflunisal—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Diflunisal—Confusional state—Mitoxantrone—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Diflunisal—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00296	0.00296	CcSEcCtD
Diflunisal—Oedema—Mitoxantrone—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Diflunisal—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Diflunisal—Nausea—Fludarabine—lymphatic system cancer	0.00294	0.00294	CcSEcCtD
Diflunisal—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00292	0.00292	CcSEcCtD
Diflunisal—Shock—Mitoxantrone—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Diflunisal—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Diflunisal—Urticaria—Bleomycin—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Diflunisal—Anorexia—Vincristine—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Diflunisal—Body temperature increased—Bleomycin—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Diflunisal—Insomnia—Carmustine—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Diflunisal—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Diflunisal—Paraesthesia—Carmustine—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Diflunisal—Dyspnoea—Carmustine—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Diflunisal—Somnolence—Carmustine—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Diflunisal—Anorexia—Mitoxantrone—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Diflunisal—Decreased appetite—Carmustine—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Diflunisal—Insomnia—Vincristine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Diflunisal—Paraesthesia—Vincristine—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Diflunisal—Constipation—Carmustine—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Diflunisal—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Diflunisal—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Diflunisal—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Diflunisal—Decreased appetite—Vincristine—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Diflunisal—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Diflunisal—Somnolence—Mitoxantrone—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Diflunisal—Feeling abnormal—Carmustine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Diflunisal—Fatigue—Vincristine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Diflunisal—Asthenia—Bleomycin—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Diflunisal—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Diflunisal—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Diflunisal—Constipation—Vincristine—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Diflunisal—Pruritus—Bleomycin—lymphatic system cancer	0.00257	0.00257	CcSEcCtD
Diflunisal—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Diflunisal—Fatigue—Mitoxantrone—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Diflunisal—Constipation—Mitoxantrone—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Diflunisal—Body temperature increased—Carmustine—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Diflunisal—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Diflunisal—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Diflunisal—Dysuria—Methotrexate—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Diflunisal—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Diflunisal—Body temperature increased—Vincristine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Diflunisal—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Diflunisal—Urticaria—Mitoxantrone—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Diflunisal—Hypersensitivity—Carmustine—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Diflunisal—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Diflunisal—Vomiting—Bleomycin—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Diflunisal—Rash—Bleomycin—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Diflunisal—Dermatitis—Bleomycin—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Diflunisal—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Diflunisal—Asthenia—Carmustine—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Diflunisal—Renal failure—Methotrexate—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Diflunisal—Stomatitis—Methotrexate—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Diflunisal—Hypersensitivity—Vincristine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Diflunisal—Sweating—Methotrexate—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Diflunisal—Haematuria—Methotrexate—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Diflunisal—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Diflunisal—Asthenia—Vincristine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Diflunisal—Diarrhoea—Carmustine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Diflunisal—Nausea—Bleomycin—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Diflunisal—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Diflunisal—Asthenia—Mitoxantrone—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Diflunisal—Dizziness—Carmustine—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Diflunisal—Diarrhoea—Vincristine—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Diflunisal—Hepatitis—Methotrexate—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Diflunisal—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Diflunisal—Vomiting—Carmustine—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Diflunisal—Dizziness—Vincristine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Diflunisal—Rash—Carmustine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Diflunisal—Dermatitis—Carmustine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Diflunisal—Visual impairment—Methotrexate—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Diflunisal—Headache—Carmustine—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Diflunisal—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Diflunisal—Tinnitus—Methotrexate—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Diflunisal—Vomiting—Vincristine—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Diflunisal—Rash—Vincristine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Diflunisal—Dermatitis—Vincristine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Diflunisal—Headache—Vincristine—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Diflunisal—Nausea—Carmustine—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Diflunisal—Vomiting—Mitoxantrone—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Diflunisal—Rash—Mitoxantrone—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Diflunisal—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Diflunisal—Headache—Mitoxantrone—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Diflunisal—Nausea—Vincristine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Diflunisal—Nausea—Mitoxantrone—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Diflunisal—Vision blurred—Methotrexate—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Diflunisal—Vertigo—Methotrexate—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Diflunisal—Chest pain—Methotrexate—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Diflunisal—Confusional state—Methotrexate—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Diflunisal—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Diflunisal—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Diflunisal—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Diflunisal—Anorexia—Methotrexate—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Diflunisal—Insomnia—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Diflunisal—Paraesthesia—Methotrexate—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Diflunisal—Dyspnoea—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Diflunisal—Somnolence—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Diflunisal—Dyspepsia—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Diflunisal—Decreased appetite—Methotrexate—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Diflunisal—Fatigue—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Diflunisal—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Diflunisal—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Diflunisal—Urticaria—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Diflunisal—Body temperature increased—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Diflunisal—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Diflunisal—Asthenia—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Diflunisal—Pruritus—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Diflunisal—Diarrhoea—Methotrexate—lymphatic system cancer	0.001	0.001	CcSEcCtD
Diflunisal—Dizziness—Methotrexate—lymphatic system cancer	0.000971	0.000971	CcSEcCtD
Diflunisal—Vomiting—Methotrexate—lymphatic system cancer	0.000933	0.000933	CcSEcCtD
Diflunisal—Rash—Methotrexate—lymphatic system cancer	0.000926	0.000926	CcSEcCtD
Diflunisal—Dermatitis—Methotrexate—lymphatic system cancer	0.000925	0.000925	CcSEcCtD
Diflunisal—Headache—Methotrexate—lymphatic system cancer	0.00092	0.00092	CcSEcCtD
Diflunisal—Nausea—Methotrexate—lymphatic system cancer	0.000872	0.000872	CcSEcCtD
